Page last updated: 2024-10-27

gentamicin and Epidermolysis Bullosa, Junctional

gentamicin has been researched along with Epidermolysis Bullosa, Junctional in 6 studies

Gentamicins: A complex of closely related aminoglycosides obtained from MICROMONOSPORA purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. They act to inhibit PROTEIN BIOSYNTHESIS.

Epidermolysis Bullosa, Junctional: Form of epidermolysis bullosa having onset at birth or during the neonatal period and transmitted through autosomal recessive inheritance. It is characterized by generalized blister formation, extensive denudation, and separation and cleavage of the basal cell plasma membranes from the basement membrane.

Research Excerpts

ExcerptRelevanceReference
"Gentamicin-treated wounds exhibited increased expression of laminin 332 at the dermal-epidermal junction for at least 3 months and were associated with improved wound closure."2.94Gentamicin Induces Laminin 332 and Improves Wound Healing in Junctional Epidermolysis Bullosa Patients with Nonsense Mutations. ( Antaya, R; Chen, M; Chen, Q; Cogan, J; Hao, M; Hou, Y; Kim, G; Kwong, A; Lincoln, V; Woodley, DT, 2020)
"Gentamicin application was well tolerated, long hospitalization was not required."1.51Attenuation of Severe Generalized Junctional Epidermolysis Bullosa by Systemic Treatment with Gentamicin. ( Hammersen, J; Neuner, A; Schneider, H; Wild, F, 2019)

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (33.33)24.3611
2020's4 (66.67)2.80

Authors

AuthorsStudies
Mosallaei, D1
Hao, M3
Antaya, RJ1
Levian, B1
Kwong, A2
Cogan, J3
Hamilton, C1
Schwieger-Briel, A1
Tan, C1
Tang, X1
Woodley, DT3
Chen, M3
Li, Y1
Shen, J1
Liang, J1
Zheng, L1
Chen, F1
Yao, Z1
Li, M1
Hou, Y2
Antaya, R1
Kim, G1
Lincoln, V2
Chen, Q1
Hung, JH1
Hou, PC1
Huang, FC1
Hsu, CK1
Hirsch, M1
Alexeev, V1
De Luca, M1
De Rosa, L1
Bauer, JW1
Hammersen, J1
Neuner, A1
Wild, F1
Schneider, H1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Pilot Study of the Restoration of Functional Laminin 332 in JEB Patients With Nonsense Mutations After Topical and Intravenous Gentamicin Treatment[NCT03526159]Phase 1/Phase 26 participants (Anticipated)Interventional2018-06-01Recruiting
Optimization of Intravenous Gentamicin Treatment to Restore Functional Laminin 332 in JEB Patients With Nonsense Mutations[NCT04140786]Phase 1/Phase 26 participants (Anticipated)Interventional2019-10-31Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

2 trials available for gentamicin and Epidermolysis Bullosa, Junctional

ArticleYear
Molecular and Clinical Outcomes After Intravenous Gentamicin Treatment for Patients With Junctional Epidermolysis Bullosa Caused by Nonsense Variants.
    JAMA dermatology, 2022, 04-01, Volume: 158, Issue:4

    Topics: Alleles; Child; Epidermolysis Bullosa, Junctional; Female; Gentamicins; Humans; Infant; Laminin; Mal

2022
Molecular and Clinical Outcomes After Intravenous Gentamicin Treatment for Patients With Junctional Epidermolysis Bullosa Caused by Nonsense Variants.
    JAMA dermatology, 2022, 04-01, Volume: 158, Issue:4

    Topics: Alleles; Child; Epidermolysis Bullosa, Junctional; Female; Gentamicins; Humans; Infant; Laminin; Mal

2022
Molecular and Clinical Outcomes After Intravenous Gentamicin Treatment for Patients With Junctional Epidermolysis Bullosa Caused by Nonsense Variants.
    JAMA dermatology, 2022, 04-01, Volume: 158, Issue:4

    Topics: Alleles; Child; Epidermolysis Bullosa, Junctional; Female; Gentamicins; Humans; Infant; Laminin; Mal

2022
Molecular and Clinical Outcomes After Intravenous Gentamicin Treatment for Patients With Junctional Epidermolysis Bullosa Caused by Nonsense Variants.
    JAMA dermatology, 2022, 04-01, Volume: 158, Issue:4

    Topics: Alleles; Child; Epidermolysis Bullosa, Junctional; Female; Gentamicins; Humans; Infant; Laminin; Mal

2022
Gentamicin Induces Laminin 332 and Improves Wound Healing in Junctional Epidermolysis Bullosa Patients with Nonsense Mutations.
    Molecular therapy : the journal of the American Society of Gene Therapy, 2020, 05-06, Volume: 28, Issue:5

    Topics: Administration, Cutaneous; Anti-Bacterial Agents; Cell Adhesion Molecules; Cell Survival; Cells, Cul

2020

Other Studies

4 other studies available for gentamicin and Epidermolysis Bullosa, Junctional

ArticleYear
Gentamicin induces COL17A1 nonsense mutation readthrough in junctional epidermolysis bullosa.
    The Journal of dermatology, 2020, Volume: 47, Issue:3

    Topics: Autoantigens; Codon, Nonsense; Collagen Type XVII; Epidermolysis Bullosa, Junctional; Gentamicins; H

2020
Topical gentamicin ointment induces LAMB3 nonsense mutation readthrough and improves corneal erosions in a patient with junctional epidermolysis bullosa.
    Clinical & experimental ophthalmology, 2021, Volume: 49, Issue:3

    Topics: Cell Adhesion Molecules; Codon, Nonsense; Epidermolysis Bullosa, Junctional; Gentamicins; Humans; Ka

2021
Gentamicin induces
    Proceedings of the National Academy of Sciences of the United States of America, 2018, 07-10, Volume: 115, Issue:28

    Topics: Cell Adhesion Molecules; Codon, Nonsense; Epidermolysis Bullosa, Junctional; Gentamicins; HEK293 Cel

2018
Attenuation of Severe Generalized Junctional Epidermolysis Bullosa by Systemic Treatment with Gentamicin.
    Dermatology (Basel, Switzerland), 2019, Volume: 235, Issue:4

    Topics: Anti-Bacterial Agents; Epidermolysis Bullosa, Junctional; Female; Gentamicins; Humans; Infant; Injec

2019